Granted Patent
B2
US 12,365,876 · App. 18/358,659 · Granted Jul 22, 2025
Genetically modified stem cells
Assignee:
SDF BioPharma
C12N5/0676A61K35/17A61K35/39A61P3/10C07K14/522C12N5/0635C12N5/0638C12N5/0646C12N5/0686C12N2501/998C12N2502/11C12N2502/99C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.
Claims (28)
1. A transgenic human beta cell that expresses orIL overexpresses a human fugetactic agent in an amount sufficient to render said beta cell resistant to human immune cells, wherein said beta cell is capable of expressing insulin and further wherein said fugetactic agent is selected from the group consisting of CXCL12, CXCL13, gp120, and IL8.
2. The transgenic human beta cell of claim 1 , wherein said cell is incapable of cell division.
3. The transgenic human beta cell of claim 1 , wherein said human fugetactic agent expressed by said cell is exogenous to said cell.
4. The human beta cell of claim 1 , wherein said human fugetactic agent overexpressed by said cell is endogenous to said cell.
5. The human beta cell of claim 2 , wherein said human fugetactic agent expressed by said cell is exogenous to said cell.
6. The human beta cell of claim 2 , wherein said human fugetactic agent overexpressed by said cell is endogenous to said cell.
7. The human beta cell of claim 1 , wherein said human fugetactic agent is CXCL13.
8. The human beta cell of claim 2 , wherein said human fugetactic agent is CXCL13.
9. The human beta cell of claim 1 , wherein said huma fugetactic agent is gp120.
10. The human beta cell of claim 2 , wherein said huma fugetactic agent is gp120.
11. The human beta cell of claim 1 , wherein said human fugetactic agent is IL8.
12. The human beta cell of claim 2 , wherein said human fugetactic agent is IL8.
13. A pharmaceutical composition comprising a pharmaceutical carrier and a population of human beta cells that expresses or overexpresses a human fugetactic agent in an amount sufficient to render said beta cell resistant to human immune cells, wherein said beta cell is capable of expressing insulin and further wherein said fugetactic agent is selected from the group consisting of CXCL12, CXCL13, gp120, and IL8.
14. The pharmaceutical composition of claim 13 , wherein said cell is incapable of cell division.
15. The pharmaceutical composition of claim 13 , wherein said human fugetactic agent expressed by said cell is exogenous to said cell.
16. The pharmaceutical composition of claim 13 , wherein said human fugetactic agent overexpressed by said cell is endogenous to said cell.
17. The pharmaceutical composition of claim 14 , wherein said human fugetactic agent expressed by said cell is exogenous to said cell.
18. The pharmaceutical composition of claim 14 , wherein said human fugetactic agent overexpressed by said cell is endogenous to said cell.
19. The pharmaceutical composition of claim 13 , wherein said human fugetactic agent is CXCL13.
20. The pharmaceutical composition of claim 14 , wherein said human fugetactic agent is CXCL13.
21. The pharmaceutical composition of claim 13 , wherein said human fugetactic agent is gp 120.
22. The pharmaceutical composition of claim 14 , wherein said human fugetactic agent is gp 120.
23. The pharmaceutical composition of claim 13 , wherein said human fugetactic agent is IL8.
24. The pharmaceutical composition of claim 14 , wherein said human fugetactic agent is IL8.
25. The beta cell of claim 1 , wherein said cell is allogeneic to the human immune cells.
26. The beta cell of claim 2 , wherein said cell is allogeneic to the human immune cells.
27. The human beta cell of claim 1 , wherein said cell is differentiated ex vivo from a human stem cell.
28. The human beta cell of claim 2 , wherein said cell is differentiated ex vivo from a human stem cell.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 31, 2023
From: SWISS, GERALD F.; KIEWLICH, DAVID
To: WALLKILL BIOPHARMA, INC.
Reel/Frame 064440/0878 →
CHANGE OF NAME
Recorded Jul 31, 2023
From: WALLKILL BIOPHARMA INC.
To: SDF BIOPHARMA INC.
Reel/Frame 064445/0218 →
Continuity (15)
Provisional Application
62734910
· Sep 21, 2018
Provisional Application
62719975
· Aug 20, 2018
Provisional Application
62717587
· Aug 10, 2018
Provisional Application
62696603
· Jul 11, 2018
Provisional Application
62694634
· Jul 6, 2018
Provisional Application
62662651
· Apr 25, 2018
Provisional Application
62637913
· Mar 2, 2018
Provisional Application
62568117
· Oct 4, 2017
Provisional Application
62567604
· Oct 3, 2017
References Cited (142)
US 5756084A
· Honjo et al.
· 1998
[cited by applicant]
US 6448054B1
· Poznansky et al.
· 2002
[cited by applicant]
US 7033831B2
· Fisk et al.
· 2006
[cited by applicant]
US 7776564B2
· Chu et al.
· 2010
[cited by applicant]
US 8268620B2
· Thomson et al.
· 2012
[cited by applicant]
US 8546140B2
· Mack et al.
· 2013
[cited by applicant]
US 20040043040A1
· Dunussi-Joannopoulos
· 2004
[cited by applicant]
US 20070258943A1
· Penn et al.
· 2007
[cited by applicant]
US 20080213319A1
· Kang et al.
· 2008
[cited by applicant]
US 20090280096A1
· Kubo et al.
· 2009
[cited by applicant]
US 20120053119A1
· Habener et al.
· 2012
[cited by applicant]
US 20170196913A1
· Ben-Porath et al.
· 2017
[cited by applicant]
US 20190100729A1
· Kiewlich et al.
· 2019
[cited by applicant]
US 20190100730A1
· Swiss et al.
· 2019
[cited by applicant]
WO 2012025925A1
· 2012
[cited by applicant]
Transplantation, 2007, vol. 83, No. 2, pp. 174-183.
[cited by applicant]
United States Patent and Trademark Office, Notice of Allowance in U.S. Appl. No. 16/370,606 mailed Apr. 20, 2020.
[cited by applicant]
Urnov, F. D., et al., “Genome editing with engineered zinc finger nucleases,” Nature Reviews Genetics 11 (9): 636-646, 2010.
[cited by applicant]
Van Craenenbroeck, K., et al., “Episomal vectors for gene expression in mammalian cells,” European Journal of Biochemistry 267(18): 5665-5678, 2000.
[cited by applicant]
Vianello et al., “Fugetaxis: active movement of leukocytes away from a chemokinetic agent,” J. Mol. Med., 2005, 83:752-763.
[cited by applicant]
Votey, M., et al., “Of Mice and Men: How the NPOD Program Is Changing the Way Researchers Study Type 1 Diabetes,” DiaTribe, Aug. 21, 2015 (2 pages), diatribe.org/mice-and-men-how-npod-program-changing-wav-researchers-st…
[cited by applicant]
Walsh, N. C., et al., “Humanized mouse models of clinical disease,” Annual Review of Pathology: Mechanisms of Disease 12: 187-215, 2017.
[cited by applicant]
Wernig, M., et al., “In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state,” Nature 448(7151): 318-325, 2007.
[cited by applicant]
Xiao, H., et al., “Angelica sinensis Polysaccharides Ameliorate Stress-Induced Premature Senescence of Hematopoietic Cell via Protecting Bone Marrow Stromal Cells from Oxidative Injuries Caused by 5-Fluorouracil,” Int. …
[cited by applicant]
Yang, H., et al., “Human β Cells Are Exceedingly Resistant to Streptozotocin in Vivo,” Endocrinology, 2002, 143(7): 2491-2495.
[cited by applicant]
Yano, T., et al., “Stromal cell-derived factor-1 (SDF-1/CXCL 12) attenuates diabetes in mice and promotes pancreatic beta-cell survival by activation of the prosurvival kinase Akt,” Diabetes, 2007, 56(12): 2946-57.
[cited by applicant]
Yu, J., et al., “Induced pluripotent stem cell lines derived from human somatic cells,” Science 318: 1917-1920, 2007.
[cited by applicant]
Yu et al., “Identification and expression of novel isoforms of human stromal cell-derived factor 1,” Gene, 2006, 374: 174-179.
[cited by applicant]
Zhang, Z., et al., “CRISPR/Cas9 genome-editing system in human stem cells: current status and future prospects,” Molecular Therapy-Nucleic Acids 9: 230-241, 2017.
[cited by applicant]
Zhang, L., et al., “CXCL 12 overexpression promotes the angiogenesis potential of periodontal ligament stem cells,” Sci. Rep., 2017, 7: 10286.
[cited by applicant]
Zhong, Y., et al., “Targeting Interleukin-2-inducible T-cell Kinase (ITK) and Resting Lymphocyte Kinase (RLK) Using a Novel Covalent Inhibitor PRN694,” J. Biol. Chem., 2015, 290(10): 5960-5978.
[cited by applicant]
Mali, P., et al., “RNA-guided human genome engineering via Cas9,” Science 339(6121): 823-826, 2013.
[cited by applicant]
Massachusetts General Hospital, “Protein that repels immune cells protects transplanted pancreatic islets from rejection: Transplanting islets encapsulated with CXCL12 restores blood sugar control without immunosuppress…
[cited by applicant]
Mestas, J., et al., “Of mice and not men: differences between mouse and human immunology,” The Journal of Immunology, 2004, 172(5): 2731-2738.
[cited by applicant]
Miller, J.C., et al., “A TALE nuclease architecture for efficient genome editing,” Nature Biotechnology29(2): 143-150, 2010.
[cited by applicant]
Millette, K., et al., “Gene Editing and Human Pluripotent Stem Cells: Tools for Advancing Diabetes Disease Modeling and Beta-Cell Development,” Current Diabetes Reports 17(11): 116, 2017.
[cited by applicant]
Millman, J. R., et al., “Generation of stem cell-derived B-cells from patients with type 1 diabetes,” Nature Communications 7: 11463 (May 10, 2016) (9 pages).
[cited by applicant]
Naparstek, Y., et al., “Effector T lymphocyte line cells migrate to the thymus and persist there,” Nature, 1982, 300: 262-264. [Abstract only].
[cited by applicant]
Narayanavari, S. A., et al., “Sleeping Beauty transposon vectors for therapeutic applications: advances and challenges,” Cell and Gene Therapy Insights 3(2) (2017) (28 pages).
[cited by applicant]
Notice of Reasons for Rejection in related Japanese Application No. 2020-519249, pp. 1-13.
[cited by applicant]
Okita, K., et al., “Generation of germline-competent induced pluripotent stem cells,” Nature 448(7151): 313-318, 2007.
[cited by applicant]
Olivier, V., et al., “Comparative particle-induced cytotoxicity toward macrophages and fibroblasts,” Cell Biology and Toxicology, 2003, 19: 145-159.
[cited by applicant]
Orimo, A., et al., “Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL 12 Secretion,” Cell, 2005, 121: 335-348.
[cited by applicant]
Orlando, G., et al., “Cell replacement strategies aimed at reconstitution of the β-cell compartment in type 1 diabetes,” Diabetes63(5): 1433-1444, 2014.
[cited by applicant]
Oumard, A., et al., “Recommended method for chromosome exploitation: RMCE-based cassette-exchange systems in animal cell biotechnology,” Cytotechnology 50.1-3 (2006): 93-108.
[cited by applicant]
Pagliuca, F. W., et al., “How to make a functional β-cell,” Development, 2013, 140(12): 2472-2483.
[cited by applicant]
Papeta, N., et al., “Long-term survival of transplanted allogeneic cells engineered to express a T cell chemorepellent,” Transplantation, 2007, 83(2): 174-183.
[cited by applicant]
Park, I., et al., “Reprogramming of human somatic cells to pluripotency with defined factors,” Nature 451: 141-145, 2008.
[cited by applicant]
Penn, M.S., et al., “SDF-1 in myocardial repair,” Gene Therapy, 2012, 19: 583-587.
[cited by applicant]
Pericin et al., “Allogeneic β-islet cells correct diabetes and resist immune rejection,” PNAS, 2002, 99(12): 8203-8206.
[cited by applicant]
Perl, S., et al., “Significant human β-cell turnover is limited to the first three decades of life as determined by in vivo thymidine analog incorporation and radiocarbon dating,” The Journal of Clinical Endocrinology &…
[cited by applicant]
Perlman, R., “Mouse models of human disease: An evolutionary perspective,” Eval. Med. Public Health, 2016, 2016 (1): 170-176.
[cited by applicant]
Petrova, N. V., et al., “Small molecule compounds that induce cellular senescence,” Aging Cell 15(6): 999-1017, 2016.
[cited by applicant]
PLOS ONE, 2013, vol. 8, Issue 3, e59679.
[cited by applicant]
Porteus, M. H., et al., “Gene targeting using zinc finger nucleases,” Nature Biotechnology 23(8): 967-973, 2005.
[cited by applicant]
Poznansky et al., “Thymocyte emigration is mediated by active movement away from stroma-derived factors,” J. Clin. Invest., 2002, 109(8): 1101-1110.
[cited by applicant]
Poznansky, M. C., et al., “Active movement of T cells away from a chemokine,” Nature Medicine 6(5): 543-548, 2000.
[cited by applicant]
Qadir, M. M. F., et al., “P2RY1/ALK3-Expressing Cells within the Adult Human Exocrine Pancreas Are BMP-7 Expandable and Exhibit Progenitor-like Characteristics,” Cell Reports 22(9): 2408-2420, 2018.
[cited by applicant]
Qi, M., “Transplantation of encapsulated pancreatic islets as a treatment for patients with type 1 diabetes mellitus,” Advances in Medicine, vol. 2014 (2014) (15 pages).
[cited by applicant]
Rabinovitch, A., et al., “Transfection of Human Pancreatic Islets With an Anti-Apoptotic Gene (bcl-2) Protects β-Cells From Cytokine-Induced Destruction,” Diabetes, 1999, 48(6): 1223-1229.
[cited by applicant]
Reply Brief filed Feb. 24, 2021 in U.S. Appl. No. 16/146,980.
[cited by applicant]
“Researchers find striking differences between human and animal insulin-producing islet cells,” Diabetes Research Institute Foundation Press Release, Feb. 2006, available at: https://www.diabetesresearch.org/differences…
[cited by applicant]
Reyon, D., et al., “FLASH assembly of TALENs for high-throughput genome editing,” Nature Biotechnology 30(5): 460-465, 2012.
[cited by applicant]
Ricordi, C., “Lilly Lecture 2002—Islet Transplantation: A Brave New World,” Diabetes, 2003, 52: 1595-1603.
[cited by applicant]
Roep, B. O., et al., “Animal models have little to teach us about Type 1 diabetes: 1. In support of this proposal,” Diabetologia, 2004, 47(10): 1650-1656.
[cited by applicant]
Route of administration. (n.d.). In Wikipedia. Retrieved Aug. 19, 2020, from https://en.wikipedia.ora/wiki/Route_of_administration.
[cited by applicant]
Russ, H. A., et al., “Controlled induction of human pancreatic progenitors produces functional beta-like cells in vitro,” The EMBO Journal 34(13): 1759-1772, 2015.
[cited by applicant]
Sakata, N., et al., “Encapsulated islets transplantation: past, present and future,” World Journal of Gastrointestinal Pathophysiology, 2012, 3(1): 19-26.
[cited by applicant]
Schuetz, C., et al., “Islet cell transplantation: update on current clinical trials,” Current Transplantation Reports 3(3): 254-263, 2016.
[cited by applicant]
Shi, Y., et al., “Inducing embryonic stem cells to differentiate into pancreatic β cells by a novel three-step approach with activin A and all-trans retinoic acid,” Stem Cells 23(5): 656-662, 2005.
[cited by applicant]
Sneddon et al., Stem Cell Therapies for Treating Diabetes; Progress and Remaining Challenges, Cell Stem Cell 2018, 22: 810-818.
[cited by applicant]
Sremac et al., “Preliminary Studies of the Impact of CXCL12 on the Foreign Body Reaction to Pancreatic Islets Microencapsulated in Alginate in Nonhuman Primates,” Transplantation Direct, 2019, 5(5): e447.
[cited by applicant]
Stewart, D., “CRISPR-Cas9 DNA Editing Possibly Linked to Cancer, But CRISPR-Cas13d RNA Editing Could Offer New Avenues for Treatment,” Dark Daily, Nov. 7, 2018, available at: https://www.darkdaily.com/crispr-cas9-dna-ed…
[cited by applicant]
Sundararaman, S., et al., “Plasmid-based transient human stromal cell-derived factor-1 gene transfer improves cardiac function in chronic heart failure,” Gene Therapy, 2011, 18: 867-873.
[cited by applicant]
Takahashi, K., et al., “Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors,” Cell 126(4): 663-676, 2006.
[cited by applicant]
Takahashi, K., et al., “Induction of pluripotent stem cells from adult human fibroblasts by defined factors,” Cell 131 (5): 861-872, 2007.
[cited by applicant]
Tateishi, K., et al., “Generation of insulin-secreting islet-like clusters from human skin fibroblasts,” Journal of Biological Chemistry 283(46): 31601-31607, 2008.
[cited by applicant]
Tatum, J. A., et al., “Single-donor islet transplantation in type 1 diabetes: patient selection and special considerations,” Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 10: 73-78, 2017.
[cited by applicant]
Teta, M., et al., “Very Slow Turnover of β-Cells in Aged Adult Mice,” Diabetes, 2005, 54: 2557-2567.
[cited by applicant]
The International Bureau of WIPO, International Preliminary Report on Patentability for International Application No. PCT/US2018/053599, mailed Apr. 16, 2020.
[cited by applicant]
Tipanee, J., et al., “Preclinical and clinical advances in transposon-based gene therapy,” Bioscience Reports 37(6) (2017) (20 pages).
[cited by applicant]
Aboumrad et al., “The CXCR4/CXCL 12 (SDF-1) signaling pathway protects non-obese diabetic mouse from autoimmune diabetes,” Clinical and Experimental Immunology, 2007, 148(3): 432-439.
[cited by applicant]
Altenburg, J., et al., “A Naturally Occurring Splice Variant of CXCL 12/Stromal Cell-Derived Factor 1 Is a Potent Human Immunodeficiency Virus Type 1 Inhibitor with Weak Chemotaxis and Cell Survival Activities,” J. Vira…
[cited by applicant]
Altieri, P., et al., “5-fluorouracil causes endothelial cell senescence: potential protective role of glucagon-like peptide 1,” British Journal of Pharmacology, 2017, 174: 3713-3726.
[cited by applicant]
Ansari, A., et al., “Cellular GFP Toxicity and Immunogenicity: Potential Confounders in in Vivo Cell Tracking Experiments,” Stem Cell Rev., 2016, 12(5): 553-559.
[cited by applicant]
Appeal Brief filed Nov. 20, 2020 in U.S. Appl. No. 16/146,980.
[cited by applicant]
Baek, K., et al., “Gene transfection for stem cell therapy,” Current Stem Cell Reports 2(1): 52-61, 2016.
[cited by applicant]
Berezhnoi, A. E., et al., “High-dose Gamma-Irradiation Enhance Expression of Transgene Under Control of Immediate-Early CMV Promoter in Stably Transfected Tumor Cells,” Mol. Biol. (Mosk), 2008, 42(3): 501-509. [Abstract…
[cited by applicant]
Bhatt, J.M., et al., “Expression of Epitope-Tagged Proteins in Mammalian Cells in Culture,” Methods Mol. Biol., 2016, 1474: 3-24 [Abstract].
[cited by applicant]
Brehm, M. A., et al., “Advancing animal models of human type 1 diabetes by engraftment of functional human tissues in immunodeficient mice,” Cold Spring Harbor Perspectives in Medicine 2(5): a007757, 2012.
[cited by applicant]
Cabrera, O ., et al., “The unique cytoarchitecture of human pancreatic islets has implications for islet cell function,” Proceedings of the National Academy of Sciences 103(7): 2334-2339, 2006.
[cited by applicant]
Cerignoli, F., et al., “In vitro immunotherapy potency assays using real-time cell analysis,” PLOS One, 2018, available at: https://doi.org/10.1371/journal.pone.0193498.
[cited by applicant]
Cermak, T., et al., “Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting,” Nucleic Acids Research 39(12): e82, 2011 (11 pages).
[cited by applicant]
Charles, M.A., et al., “Immune islet killing mechanisms associated with insulin-dependent diabetes: in vitro expression of cellular and antibody-mediated islet cell cytotoxicity in humans,” J. Immunol., 1983, 130(3): 11…
[cited by applicant]
Chira, S., et al., “Progresses towards safe and efficient gene therapy vectors,” Oncotarget 6(31): 30675-30703, 2015.
[cited by applicant]
Chong et al., “Lessons and Limits of Mouse Models,” Cold Spring Harb. Perspect. Med., 2013, 3(12): 1-16.
[cited by applicant]
“Cloning Technique Used to Create Pancreatic Cells for Type 1 Diabetes.” Diabetes Community, Support, Education, Recipes & Resources, Apr. 29, 2014 (4 pages), www.diabetes.co.uknews/2014/apr/cloning-technique-used-to-cr…
[cited by applicant]
Collier, J. J., et al., “Pro-and antiapoptotic proteins regulate apoptosis but do not protect against cytokine-mediated cytotoxicity in rat islets and β-cell lines,” Diabetes 55(5): 1398-1406, 2006.
[cited by applicant]
Cong, L., et al., “Multiplex genome engineering using CRISPR/Cas systems,” Science (2013): 819-823.
[cited by applicant]
Copenhaver, M., et al., “Type 1 diabetes: where are we in 2017?,” Transl. Pediatr., 2017, 6(4): 359-364.
[cited by applicant]
El-Haibi, C.P., et al., “CXCL 13 mediates prostate cancer cell proliferation through JNK signalling and invasion through ERK activation,” Cell Proliferation 44(4) (2011) (16 pages).
[cited by applicant]
European Patent Office, International Search Report and Written Opinion for International Application No. PCT/US2018/053599, mailed Nov. 28, 2018.
[cited by applicant]
Examiner's Answer mailed Dec. 28, 2020 in in U.S. Appl. No. 16/146,980.
[cited by applicant]
Final Office Action mailed Jun. 29, 2020 in U.S. Appl. No. 16/146,980.
[cited by applicant]
Final Office Action dated Jan. 31, 2023 for U.S. Appl. No. 16/633,744, 9 pgs.
[cited by applicant]
Focaccetti, C., et al., “Effects of 5-Fluorouracil on Morphology, Cell Cycle, Proliferation, Apoptosis, Autophagy and ROS Production in Endothelial Cells and Cardiomyocytes,” PLoS ONE, 2015, 10(2): e0115686. doi: 10.137…
[cited by applicant]
GenBank E09668.1, cDNA encoding human SDF-1 alpha, 2005 (2 pages).
[cited by applicant]
GenBank E09669.1, cDNA of human SDF-1 beta isoform, 2005 (2 pages).
[cited by applicant]
Gonzalez, F., et al., “An iCRISPR platform for rapid, multiplexable, and inducible genome editing in human pluripotent stem cells,” Cell Stem Cell 15(2): 215-226, 2014.
[cited by applicant]
Goping, I. S., et al., “Cytotoxic T lymphocytes overcome Bcl-2 inhibition: target cells contribute to their own demise,” Blood 111 (4): 2142-2151, 2008.
[cited by applicant]
Götherström, C., et al., “Fetal and adult multipotent mesenchymal stromal cells are killed by different pathways,” Cytotherapy, 2011, 13(3): 269-278.
[cited by applicant]
Hardee, C.L., et al. “Advances in non-viral DNA vectors for gene therapy,” Genes 8(65) (2017) (22 pages).
[cited by applicant]
He, X., et al., “Knock-in of large reporter genes in human cells via CRISPR/Cas9-induced homology-dependent and independent DNA repair,” Nucleic Acids Research 44(9) (2016): e85-e85.
[cited by applicant]
Helman, A., et al., “p161nk4a_induced senescence of pancreatic beta cells enhances insulin secretion,” Nature Medicine, 2016, 22(4): 412-422.
[cited by applicant]
Herberts, C., et al., “Risk factors in the development of stem cell therapy,” J. Transl. Med., 2011, 9: 29.
[cited by applicant]
Hockemeyer, D., et al., “Genetic engineering of human pluripotent cells using TALE nucleases,” Nature Biotechnology 29(8): 731, 2011.
[cited by applicant]
Hsu, P. D., et al., “Development and applications of CRISPR-Cas9 for genome engineering,” Cell 157(6): 1262-1278, 2014.
[cited by applicant]
Ilhan, A., et al., “CXCL12/SDF-1 over-expression in human insulinomas and its biological relevance,” Molecular and Cellular Endocrinology, 2009, 298: 1-10.
[cited by applicant]
Johannesson, B., et al., “Toward beta cell replacement for diabetes,” The EMBO Journal 34(7): 841-855, 2015.
[cited by applicant]
Joung, J. K., et al., “TALENs: a widely applicable technology for targeted genome editing,” Nature Reviews Molecular Cell Biology 14(1): 49-55, 2013.
[cited by applicant]
Kaja, S., et al., “Quantification of Lactate Dehydrogenase for Cell Viability Testing Using Cell Lines and Primary Cultured Astrocytes,” Current Protocols in Toxicology, 2017, Suppl 72: 2.26.1-2.26.10.
[cited by applicant]
Kelly, O. G., et al., “Cell-surface markers for the isolation of pancreatic cell types derived from human embryonic stem cells,” Nature Biotechnology 29(8) (2011) (9 pages).
[cited by applicant]
Kiewlich Declaration signed Feb. 7, 2020, and submitted in U.S. Appl. No. 16/146,980.
[cited by applicant]
Kiewlich Declaration signed Nov. 20, 2019, and submitted in U.S. Appl. No. 16/370,606.
[cited by applicant]
King, A., “The use of animal models in diabetes research,” British Journal of Pharmacology, 2012, 166: 877-894.
[cited by applicant]
Kroon, E., et al., “Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo,” Nature Biotechnology 26(4): 443-452, 2008.
[cited by applicant]
Leach, C., “The Mouse Trap,” Insulin Nation, Nov. 18, 2013, available at: https://insulinnation.com/treatment/cure-insight/the-mouse-trap/.
[cited by applicant]
Liang, X., et al., “Human bone marrow mesenchymal stem cells expressing SDF-1 promote hematopoietic stem cell function of human mobilised peripheral blood CD34+ cells in vivo and in vitro,” Int. J. Radiat. Biol., 2010, …
[cited by applicant]
Lowry, W. E., et al., “Generation of human induced pluripotent stem cells from dermal fibroblasts,” Proceedings of the National Academy of Sciences 105(8): 2883-2888, 2008.
[cited by applicant]
Luther, S. A., et al., “Differing activities of homeostatic chemokines CCL 19, CCL21, and CXCL 12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis,” The Journal of Immunology 169(1): 424-433, 2002.
[cited by applicant]
Maherali, N., et al., “Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution,” Cell Stem Cell 1(1): 55-70, 2007.
[cited by applicant]